Remus Pharma Share Price

Remus Pharmaceuticals Limited, with its corporate operations in Ahmedabad, functions as a pharmaceutical marketing and distribution company in India. The company was incorporated in 2015 and is headquartered in Gujarat. Remus Pharmaceuticals engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products. The company also deals in active pharmaceutical ingredients and provides technical consultancy services to various distributors for the preparation of reports on product dossiers, along with offering contract manufacturing services. 

Remus Pharmaceuticals share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical marketing sector. The company’s financial health depends on the volume of finished formulations marketed, API trading margins, distributor network expansion, and new product launches. Remus Pharmaceuticals stock price is influenced by various factors such as earnings, regulatory changes from the Central Drugs Standard Control Organization, drug price controls under the National Pharmaceutical Pricing Authority, and competition from larger pharmaceutical companies. In the longer run, strategies such as expansion of the product portfolio into new therapeutic segments, enhancement of the contract manufacturing business, and deepening of technical consultancy services affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

Remus Pharmaceuticals live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Remus Pharmaceuticals live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Remus Pharmaceuticals stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. 

Remus Pharmaceuticals Limited Company Fundamentals 

A. Company Background

Remus Pharmaceuticals Limited was incorporated in 2015 and is engaged in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally. The company operates primarily in the pharmaceutical marketing and distribution segment, supplying products such as finished formulations, capsules, and other pharmaceutical drugs, as well as dealing in active pharmaceutical ingredients. Its operations are based in India, with a corporate office located in Ahmedabad, Gujarat. Over time, the company has expanded its product portfolio and service offerings to include technical consultancy services for various distributors and contract manufacturing services. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and distributor network expansion. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical marketing and distribution sector. Overall fundamentals are influenced by raw material (API) prices, regulatory approvals, demand for generic drugs, and import-export dynamics. 

B. Company Product Lines

• Finished Formulations 

• Markets and distributes ready-to-use pharmaceutical drugs and medicines across various therapeutic categories in capsule and other dosage forms. 

• Active Pharmaceutical Ingredients 

• Deals in trading and distribution of active pharmaceutical ingredients for use in drug manufacturing and contract manufacturing. 

• Technical Consultancy Services 

• Provides consultancy services to various distributors for the preparation of reports on the dossiers of products. 

• Contract Manufacturing Services 

• Offers contract manufacturing services for pharmaceutical products for third-party companies. 

C. Company Revenue Model

• Marketing and Distribution Income 

• Revenue generated through the marketing, trading, and distribution of finished formulations to distributors and institutional buyers. 

• API Trading Income 

• Revenue from the trading and distribution of active pharmaceutical ingredients to pharmaceutical manufacturers. 

• Consultancy Service Fees 

• Income from technical consultancy services provided to distributors for dossier preparation and product registration. 

• Contract Manufacturing Income 

• Revenue from contract manufacturing services provided to third-party pharmaceutical companies. 

Revenue performance is primarily influenced by demand for generic drugs, API price fluctuations, distributor network expansion, and regulatory approvals for new products. 

D. Geographic Presence

• Corporate Office 

• Administrative and management functions based in Ahmedabad, Gujarat, India. 

• Distribution Network 

• Domestic distribution across India through a network of pharmaceutical distributors. 

• Export Markets 

• Products are marketed, traded, and distributed in international markets. 

• Consultancy Clients 

• Technical consultancy services provided to various distributors domestically and internationally. 

E. Key Milestones

• 2015: Incorporation of Remus Pharmaceuticals Limited. 

• 2023: Initial public offering and listing on NSE EMERGE platform. 

• 2024: Declaration of bonus issue of shares. 

• Recent years: Continued focus on expanding the product portfolio and distributor network. 

F. Industry Perspective

The pharmaceutical marketing and distribution industry is closely linked to healthcare demand, regulatory policies, and generic drug adoption. Demand trends are influenced by disease prevalence, healthcare infrastructure spending, and insurance penetration. The industry faces fluctuations in API prices, regulatory approvals, and competitive pricing from larger pharmaceutical companies. Drug price control mechanisms under the National Pharmaceutical Pricing Authority and regulations from the Central Drugs Standard Control Organisation shape business practices. Companies in this sector must manage regulatory compliance, distribution logistics, and pricing pressures while maintaining efficient supply chains. These factors collectively influence financial performance and investor perception of firms like Remus Pharmaceuticals. 

Remus Pharmaceuticals Limited Stock Market Presence: Listings and Index Representation 

Remus Pharmaceuticals Limited is listed on the National Stock Exchange under the symbol REMUS. Remus Pharmaceuticals share price is actively traded on the NSE EMERGE platform. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, Remus Pharmaceuticals stock price is generally tracked by investors interested in the pharmaceutical marketing and distribution industry. 

Remus Pharmaceuticals Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of the Nifty SME Emerge index. Remus Pharmaceuticals share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical marketing and distribution companies. 

Remus Pharmaceuticals Limited Stock Performance and Share Price History 

Remus Pharmaceuticals share price on the stock exchange reflects its position as a pharmaceutical marketing and distribution company in India. Its performance is qualitatively driven by factors such as growth in finished formulations distribution, API trading margins, expansion of the distributor network, and the ability to secure new product approvals. Investors compare Remus Pharmaceuticals share price current movement with other pharmaceutical distribution companies to assess relative strength. 

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported the stock at various points. Beyond operational and sector influences, corporate actions, such as the company’s bonus issue of shares in 2024, have significantly affected Remus Pharmaceuticals share price movements by reshaping future growth expectations and investor sentiment. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by drug price controls and API sourcing cycles. 

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by Remus Pharmaceuticals share price annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger distribution revenue and stable margins, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of healthcare policies, global API price trends, and earnings visibility, providing a framework for understanding historical performance. 

Remus Pharmaceuticals share price behaviour mirrors the trading patterns of a small-cap pharmaceutical marketing company within India’s drug distribution ecosystem. The company’s product portfolio spanning finished formulations and API trading has shaped its price history. Since its IPO listing in May 2023, Remus Pharmaceuticals share price has experienced periods of sharp gains followed by phases of consolidation. For instance, it delivered positive returns in certain periods when the company announced bonus issues and strong earnings, but recorded negative returns in other periods, underperforming broader market indices at times. Remus Pharmaceuticals share price has shown higher volatility compared to the overall market, typical for SME-listed stocks. 

The company’s performance has closely tracked India’s generic drug demand and API price cycles. Positive momentum in Remus Pharmaceuticals share price appeared during the post-IPO period, driven by increased distribution volumes and bonus issue announcements. However, periods of high API procurement costs, regulatory delays in product approvals, and competitive pressure from larger distributors have led to consolidation in Remus Pharmaceuticals share price. Profitability has shown variability in recent quarters, primarily due to API price volatility and operating expense management. 

Despite industry-wide disruptions, Remus Pharmaceuticals shares showed resilience during its growth phase. The company’s focused business model and niche positioning helped the stock recover from fluctuations. The company maintains a lean operational structure and continues to expand its product portfolio. 

Remus Pharmaceuticals share price has declined for several recurring reasons. A drop in demand for specific finished formulations directly impacts distribution revenue and leads to selling pressure. Changes in government policy regarding drug price controls or import duties on APIs can also cause the stock to fall. Moreover, increases in operational costs such as API procurement or logistics expenses without matching price increases squeeze margins, making the stock less attractive. Periods of global economic slowdown that affect healthcare spending in export markets raise concerns about international sales, leading to price declines. Remus Pharmaceuticals share price is sensitive to regulatory developments; if the CDSCO denies approval for a key product, it can cause the stock to fall as investors adjust expectations for future revenue growth. Broader market selloffs in small-cap stocks also pull Remus Pharmaceuticals share price lower, regardless of the company’s individual performance. Lower distribution volumes or reduced API trading margins directly hurts revenue, resulting in a lower valuation. 

Remus Pharmaceuticals Limited Investor Relevance and Role in Portfolio 

Remus Pharmaceuticals Limited is a holding in small-cap and pharmaceutical sector portfolios, offering exposure to finished formulations marketing, API trading, and contract manufacturing services. Its inclusion in the Nifty SME Emerge index underscores its importance in India’s pharmaceutical distribution space. The company’s position as a focused pharmaceutical marketer and distributor, together with its technical consultancy services and contract manufacturing capabilities, makes it a consideration for long-term allocations. 

Remus Pharmaceuticals share price is influenced by the company’s ownership structure. Remus Pharmaceuticals’ equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake, reflecting strong internal control as part of the founding family. Foreign institutional investors hold a modest fraction of the company’s shares. Mutual funds do not hold any significant stake. The public holds the remaining stake. The company’s management includes the founders Arpit Deepak Kumar Shah and Roma Vinodbhai Shah. This investor base, with stable promoter participation, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical marketing and distribution. 

Beyond fundamentals and ownership, Remus Pharmaceuticals stock price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on API prices, regulatory approvals, and healthcare policy announcements. The stock is available for trading on the NSE EMERGE platform, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in drug price control orders. 

Technical indicators provide additional insight into short-term momentum shifts in Remus Pharmaceuticals share price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, Remus Pharmaceuticals share price beta indicates lower volatility compared to the broader market. The company’s debt to equity ratio reflects a low to moderate use of leverage. Return on equity and return on capital employed are at modest levels, and the company’s book value per share serves as a reference point for valuation. 

Overall, Remus Pharmaceuticals stock price demonstrates moderate volatility depending on the measurement period, with the stock generally considered to have sensitivity to sector-specific factors such as API price fluctuations, regulatory approvals, and competition in pharmaceutical distribution. 

Remus Pharmaceuticals Limited Sectoral Relevance and Peer Positioning 

Remus Pharmaceuticals Limited sector relevance stems from its decade-long presence in the pharmaceutical marketing and distribution industry, its position as a focused player in finished formulations marketing, API trading, technical consultancy services, and contract manufacturing, its product portfolio spanning capsules and other pharmaceutical dosage forms, its corporate operations based in Ahmedabad, Gujarat, its engagement in international markets for distribution of pharmaceutical finished formulations and products, and its technical consultancy services for distributor dossier preparation, establishing it as a focused small-cap pharmaceutical marketing provider supporting India’s drug distribution ecosystem. Peer comparisons with companies like Sun Pharmaceutical Industries, Divis Laboratories, Torrent Pharmaceuticals, Dr Reddy’s Laboratories, Cipla, Lupin, Mankind Pharma, and smaller SME pharma distributors like Hester Biosciences, Themis Medicare, Lincoln Pharma, Wanbury, Kopran, Kilitch Drugs, and Venus Remedies focus on product portfolio, distribution network, API sourcing, and value-added consultancy services rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API prices, drug price controls, and CDSCO approvals further highlights Remus Pharmaceuticals positioning within India’s broader pharmaceutical marketing market. 

Remus Pharmaceuticals P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from finished formulations distribution and API trading. Based on available data, the current P/E ratio stands at a certain level. The company’s profit after tax showed certain trends from the previous fiscal year to the most recent fiscal year. However, quarterly performance has shown variability, with profit after tax showing movement across recent quarters. The company’s earnings before interest and taxes for a recent quarter reflected ongoing market conditions. The net profit margin showed changes in certain quarters. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a regulatory-intensive industry. 

Alongside valuation, Remus Pharmaceuticals earnings per share provide insight into the company’s operational performance and income generation from pharmaceutical distribution and API trading. Based on available data, the company reported a basic EPS in a recent quarter that showed certain trends compared to previous quarters. The trailing twelve-month EPS stands at moderate levels. Remus Pharmaceuticals EPS for the last full fiscal year showed variability. The company has a standard face value per share. More recent quarterly performance suggests that EPS has shown responsiveness to product mix and cost management. 

Remus Pharmaceuticals market cap highlights its position as a small-cap player within India’s pharmaceutical distribution sector. Based on recent data, the company’s market capitalisation fluctuates within a range depending on the reporting period. Remus Pharmaceuticals market cap has moved in line with investor perceptions of the company’s growth potential following its IPO and subsequent bonus issue. From its listing through more recent periods, the market cap showed an increasing trend as the company expanded its product portfolio and distribution network, followed by a significant correction. This pattern reflects investor confidence during favourable pharmaceutical market cycles, followed by contraction during challenging periods impacted by API price volatility and regulatory uncertainties. This decrease mirrors the correction in Remus Pharmaceuticals share price from its annual high to recent levels. 

Finally, Remus Pharmaceuticals earnings trajectory demonstrates the impact of its operational execution in a competitive pharmaceutical distribution industry. In recent fiscal years, total income showed trends supported by the core pharmaceutical marketing business. Based on available data, the company’s revenue from operations showed certain trends across fiscal years. Total income followed a similar pattern. Profit after tax showed variability. However, quarterly performance has shown variability in certain periods. The company’s API trading segment has faced headwinds from fluctuating raw material prices and competitive pressures. However, the company continues to focus on expanding its product portfolio and deepening technical consultancy services. These developments illustrate the growth trajectory of the pharmaceutical distribution industry and the company’s position within this sector. 

Over time, Remus Pharmaceuticals market cap has moved in relation to pharmaceutical sector peers. The company’s earnings have followed a pattern typical of distribution-focused pharma businesses, with revenue performance connecting directly to API prices and finished formulation offtake. Quarterly earnings have shown variability influenced by regulatory approvals and sourcing costs. The earnings per share figure has followed the trajectory of overall profitability. The price-to-earnings multiple has varied over time, reflecting changing investor expectations about product portfolio expansion and API sourcing efficiency. When the company announces new product distribution agreements or expands its distributor network, the multiple may expand. Conversely, during periods of regulatory delays or API price volatility, the multiple may contract. Comparisons with peer pharmaceutical distribution companies help investors understand relative valuation. 

Summary 

Remus Pharmaceuticals Limited operates as a small-cap pharmaceutical marketing and distribution company with a presence in finished formulations and API trading. Remus Pharmaceuticals share price reflects investor assessment of API price trends, product approval cycles, and healthcare policies. The stock trades on the NSE EMERGE platform within the small-cap segment. Operational performance depends on distribution volumes and regulatory environment, while Remus Pharmaceuticals stock price movements are observed by market participants tracking the pharmaceutical marketing and distribution sector.